Mark Auerbach


Mr. Auerbach has been a director since 2010. He was the non-executive Chairman and audit Chairman of RCS Capital Corporation, a publicly-traded financial services company. Mr. Auerbach was formerly the Chairman of Neuro-Hitech, Inc., an early-stage pharmaceutical company. He also was a director and Chairman of the audit committee of Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals. Over the past 20 years, Mr. Auerbach has served as a director for several other companies, including Par Pharmaceutical Companies, Inc., a publicly traded manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical, Inc., Collexis Holdings, a public company that develops knowledge management software and RxElite Holdings, a company that markets specialty generic drug products. Earlier, Mr. Auerbach served as Chief Financial Officer of Central Lewmar, LLC, a national fine paper distributor. He received a BS in Accounting from Rider University.

Financial Expert